Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 19 companies, including Haina Pharmaceutical, which must clarify the specific use of raised funds and the proportion of domestic and overseas uses [1][2] - Haina Pharmaceutical submitted its application to the Hong Kong Stock Exchange on November 7, 2025, with CICC as the sole sponsor [1] - The CSRC has requested Haina Pharmaceutical to provide legal opinions on the compliance of its capital reduction procedures and the legitimacy of its historical equity changes [1][2] Group 2 - Haina Pharmaceutical is a comprehensive pharmaceutical research and manufacturing company that provides CXO services and has proprietary product pipelines [3] - According to Frost & Sullivan, Haina Pharmaceutical ranks second in China for the total number of approved clinical trials and marketing licenses during the reporting period [3] - As of June 30, 2025, Haina Pharmaceutical has 398 ongoing CXO projects, indicating a robust operational capacity in drug development and related services [3]
新股消息 | 海纳医药拟港股上市 中国证监会要求补充说明募集资金具体用途
智通财经网·2025-12-26 12:52